Full Breakdown
Appeals Court Revives Hundreds of Tylenol Lawsuits Over Alleged Autism Link
7/13/2026, 10:37:14 PM
Core Event: Federal Appeals Court Restores Plaintiffs’ Cases
On July 13 2026, the 2nd U.S. Circuit Court of Appeals in Manhattan reversed a district-court ruling that had barred expert testimony in more than 500 product-liability suits against Kenvue Inc., the maker of Tylenol. The panel held that the lower court “exceeded its discretion” by excluding three doctors who testified that prenatal acetaminophen exposure could be linked to autism and attention-deficit/hyperactivity disorder (ADHD). The cases were remanded to U.S. District Judge Denise Cote for further proceedings.
Background & Context
Acetaminophen, the active ingredient in Tylenol, has been the preferred medication for pain and fever during pregnancy for decades. In September 2025, the Trump administration publicly suggested a connection between Tylenol use in pregnancy and autism, urging expectant mothers to avoid the drug. The claim sparked intense debate within the medical community. In December 2023, Judge Cote dismissed the lawsuits, deeming the plaintiffs’ experts’ methods “unreliable.” Kenvue, spun off from Johnson & Johnson in 2023, announced a $40 billion acquisition by Kimberly-Clark in November 2025, a deal it has continued to pursue despite the litigation.
Key Figures & Groups
- Kenvue Inc. – Tylenol manufacturer, based in Summit, New Jersey.
- Kimberly-Clark Corp. – Kleenex-tissue maker acquiring Kenvue.
- Circuit Judge Guido Calabresi – Authored the 64-page appellate opinion.
- Judge Denise Cote – District judge who originally dismissed the cases.
- Expert witnesses – Andrea Baccarelli (Dean, Harvard School of Public Health), Eric Hollander (Psychiatry professor, Albert Einstein College of Medicine), Brandon Pearson (Toxicologist, Columbia University).
- Ashley Keller – Plaintiffs’ attorney.
- Retail defendants – CVS, Kroger, Target, Walgreens, Walmart.
Data & Statistics
- >500 lawsuits revived.
- Bloomberg Intelligence estimates potential settlement costs could reach billions of dollars.
- Kenvue’s share price fell 1.7 % in morning trading after the ruling; Kimberly-Clark’s stock dropped 2.7 %.
- The acquisition valued at more than $40 billion is slated to close later in 2026.
Official Statements & Responses
Kenvue reiterated that “credible, independent science shows no proven link between taking acetaminophen and autism or attention-deficit hyperactivity disorder.” The company added it will “continue to defend these cases.” Bloomberg Intelligence warned that the revived litigation could generate “thousands of new lawsuits” with settlement exposure in the billions. Kimberly-Clark said it had “carefully considered all lawsuit risks” when approving the purchase.
Criticism & Opposition
Medical societies and most physicians continue to endorse acetaminophen as safe for use in pregnancy, citing systematic reviews that find no evidence of a causal relationship with autism, intellectual disability, or ADHD. Critics of the lawsuits argue the claims rely on “junk science” and that the appellate decision does not address the underlying scientific merits.
Conflicting Reports & Gaps
- Scientific consensus: Multiple systematic reviews report no link between prenatal acetaminophen exposure and neurodevelopmental disorders.
- Plaintiffs’ position: Their experts argue the research “voluminous” and interpretable as indicating risk, a view the appellate panel deemed methodologically acceptable.
- The court’s ruling focuses solely on the admissibility of expert testimony, leaving the factual question of causation unresolved.
Verbatim Quotes
- “constitute acceptable interpretations of scientific evidence where scientists may, and in fact do, disagree.” — Guido Calabresi, 2nd U.S. Circuit Court of Appeals
- “We stand behind the safety of our product and will continue to defend these cases.” — Kenvue spokesperson, statement to CNBC
- “is a vindication for the scientific evidence our clients have presented from the outset,” — Ashley Keller, plaintiffs’ attorney
- “We are pleased that the panel unanimously found that our key experts reliably applied their scientific methods and principles,” — Ashley Keller, email to press
What’s Next
The lawsuits return to Judge Cote for a new evidentiary hearing. Both parties are expected to file additional expert reports, and the $40 billion Kenvue-Kimberly-Clark merger is scheduled to close later in 2026, pending regulatory approval.
